Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and pressures. Learn why MRK stock is a buy.

Rahway, New Jersey-based Merck & Co., Inc. (MRK) operates as a healthcare company worldwide. Valued at $256.4 billion by market cap, the company delivers health solutions through its prescription ...

MRK Stock Price, Valuation & Estimates Merck’s shares have lost 15.3% in the past year compared witha decline of 3.9% for the industry. The stock has also underperformed the sector and the S&P ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

Merck and S&P 500 Performance During 2007-08 Crisis. MRK stock declined from $52 in September 2007 (pre-crisis peak) to around $24 in March 2009 (as the markets bottomed out), implying it lost ...

Merck (MRK-0.04%) has performed poorly in the stock market this year, with the drugmaker's shares down by 5%. But zooming out helps put a different spin on this story as the pharmaceutical giant ...

Merck's strong performance in the past two years has outperformed the market. Find out why I recommend a Buy rating for MRK stock at its current price.

Merck (MRK-1.75%) is a prime example of this conundrum facing pharma investors. The drugmaker's stock is currently on a five-year winning streak, relative to standard benchmarks like the S&P 500 ...